{"organizations": [], "uuid": "2416f60c1ae3b23de524c0b98242dec41590d14a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-spero-therapeutics-appoints-david/brief-spero-therapeutics-appoints-david-melnick-as-chief-medical-officer-idUSASB0BZQB", "country": "US", "domain_rank": 408, "title": "BRIEF-Spero Therapeutics Appoints David Melnick As Chief Medical Officer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T14:35:00.000+02:00", "replies_count": 0, "uuid": "2416f60c1ae3b23de524c0b98242dec41590d14a"}, "author": "", "url": "https://www.reuters.com/article/brief-spero-therapeutics-appoints-david/brief-spero-therapeutics-appoints-david-melnick-as-chief-medical-officer-idUSASB0BZQB", "ord_in_thread": 0, "title": "BRIEF-Spero Therapeutics Appoints David Melnick As Chief Medical Officer", "locations": [], "entities": {"persons": [{"name": "david melnick", "sentiment": "negative"}, {"name": "spero", "sentiment": "none"}, {"name": "melnick", "sentiment": "none"}], "locations": [], "organizations": [{"name": "spero therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "allergan", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 37 PM / Updated 8 minutes ago BRIEF-Spero Therapeutics Appoints David Melnick As Chief Medical Officer Reuters Staff \nJan 4 (Reuters) - Spero Therapeutics Inc: \n* SPERO THERAPEUTICS APPOINTS DAVID MELNICK, M.D., AS CHIEF MEDICAL OFFICER \n* SPERO THERAPEUTICS INC - ‍PRIOR TO JOINING CO, MELNICK SERVED AS VICE PRESIDENT OF CLINICAL DEVELOPMENT FOR ANTI-INFECTIVES AT ALLERGAN SINCE 2015​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T14:35:00.000+02:00", "crawled": "2018-01-04T14:47:38.001+02:00", "highlightTitle": ""}